Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
A Roberto, MT Greco, L Legramandi, F Galli, M Galli & O Corli. (2017) A comparison between the administration of oral prolonged-release oxycodone-naloxone and transdermal fentanyl in patients with moderate-to-severe cancer pain: a propensity score analysis. Journal of Pain Research 10, pages 2123-2133.
Read now
Read now
Satoshi Inoue, Yoji Saito, Satoru Tsuneto, Etsuko Aruga, Azusa Ide & Yasuyuki Kakurai. (2017) A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain reLief). Journal of Pain Research 10, pages 1953-1962.
Read now
Read now
Stefano De Santis, Cristina Borghesi, Serena Ricciardi, Daniele Giovannoni, Alberto Fulvi, Maria Rita Migliorino & Claudio Marcassa. (2016) Analgesic effectiveness and tolerability of oral oxycodone/naloxone and pregabalin in patients with lung cancer and neuropathic pain: an observational analysis. OncoTargets and Therapy 9, pages 4043-4052.
Read now
Read now
Fabio Guerriero, Anna Roberto, Maria Teresa Greco, Carmelo Sgarlata, Marco Rollone & Oscar Corli. (2016) Long-term efficacy and safety of oxycodone–naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study. Drug Design, Development and Therapy 10, pages 1515-1523.
Read now
Read now
Articles from other publishers (24)
Anna Ozaki, Takaomi Kessoku, Kosuke Tanaka, Atsushi Yamamoto, Kota Takahashi, Yuma Takeda, Yuki Kasai, Michihiro Iwaki, Takashi Kobayashi, Tsutomu Yoshihara, Takayuki Kato, Akihiro Suzuki, Yasushi Honda, Yuji Ogawa, Akiko Fuyuki, Kento Imajo, Takuma Higurashi, Masato Yoneda, Masataka Taguri, Hiroto Ishiki, Noritoshi Kobayashi, Satoru Saito, Yasushi Ichikawa & Atsushi Nakajima. (2022) Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial. Cancers 14:9, pages 2112.
Crossref
Crossref
Weiming Wang, Xinlu Wang, Yan Liu, Yuanjie Sun, Xiaoxu Liu, Yan Yan & Zhishun Liu. (2022) Effects of Electroacupuncture on Opioid-Induced Constipation in Patients With Cancer: Study Protocol for a Multicenter Randomized Controlled Trial. Frontiers in Medicine 9.
Crossref
Crossref
Brian H Le, Ghauri Aggarwal, Carol Douglas, Michael Green, Amanda Nicoll & Sam Ahmedzai. (2021) Oxycodone/naloxone prolonged‐release tablets in patients with moderate‐to‐severe, chronic cancer pain: Challenges in the context of hepatic impairment. Asia-Pacific Journal of Clinical Oncology 18:1, pages 13-18.
Crossref
Crossref
Man Soo Kim, In Jun Koh, Keun Young Choi, Sung Cheol Yang & Yong In. (2021) Efficacy of duloxetine compared with opioid for postoperative pain control following total knee arthroplasty. PLOS ONE 16:7, pages e0253641.
Crossref
Crossref
Anna Ozaki, Takaomi Kessoku, Michihiro Iwaki, Takashi Kobayashi, Tsutomu Yoshihara, Takayuki Kato, Yasushi Honda, Yuji Ogawa, Kento Imajo, Takuma Higurashi, Masato Yoneda, Masataka Taguri, Takeharu Yamanaka, Hiroto Ishiki, Noritoshi Kobayashi, Satoru Saito, Yasushi Ichikawa & Atsushi Nakajima. (2020) Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study. Trials 21:1.
Crossref
Crossref
Junya Sato, Rei Tanaka, Hiroshi Ishikawa, Tsutomu Suzuki & Michihiro Shino. (2019) A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting. Supportive Care in Cancer 28:3, pages 1083-1088.
Crossref
Crossref
Shunsuke Hayashi, Nami Suda, Takashi Kawakubo & Naohito Shimoyama. (2019) The Suppression Effect of the Opioid Receptor Antagonist, Naldemedine, for Opioid-induced Constipation and Nausea/vomitingオピオイド誘発性の便秘および嘔気・嘔吐に対するオピオイド受容体拮抗薬ナルデメジンの効果. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 45:12, pages 667-673.
Crossref
Crossref
Oscar Corli, Vittorio Iorno, Lorenzo Legramandi, Eliana Rulli, Anna Roberto, Giuseppe Azzarello, Stefania Schiavon, Luigi Cavanna, Stefano De Santis, Claudio Cartoni, Pierangelo Di Marco, Mario Dauri, Rosario Mistretta, Roberto Bortolussi, Mario Clerico, Manuela Pacchioni, Carlo Crispino, Mirko Marabese, Nicole Corsi, Silvia Natoli, Gaspare Lipari, Marta Luzi, Giovanna Palumbo & Leonardo Trentin. (2019) Oral Prolonged‐Release Oxycodone‐Naloxone: Analgesic Response, Safety Profile, and Factors Influencing the Response in Patients With Advanced Cancer. Pain Practice 19:6, pages 633-643.
Crossref
Crossref
Toshiyuki Kanemasa, Katsumi Koike, Tohko Arai, Hiroko Ono, Narumi Horita, Hiroki Chiba, Atsushi Nakamura, Yasuhide Morioka, Tsuyoshi Kihara & Minoru Hasegawa. (2019) Pharmacologic effects of naldemedine, a peripherally acting μ‐opioid receptor antagonist, in in vitro and in vivo models of opioid‐induced constipation. Neurogastroenterology & Motility 31:5, pages e13563.
Crossref
Crossref
K. Rose, M. Steiner & W. Meißner. (2018) Therapie bei Tumorschmerz: Vergleich der S3-Leitlinie der AWMF zur Palliativmedizin und der WHO-LeitlinieTreatment of cancer pain: Comparison of the German AWMF S3 guideline on palliative care and the WHO recommendations. Der Onkologe 24:11, pages 861-871.
Crossref
Crossref
M. Fallon, R. Giusti, F. Aielli, P. Hoskin, R. Rolke, M. Sharma & C.I. Ripamonti. (2018) Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Annals of Oncology 29, pages iv166-iv191.
Crossref
Crossref
P.J. Larkin, N.I. Cherny, D. La Carpia, M. Guglielmo, C. Ostgathe, F. Scotté & C.I. Ripamonti. (2018) Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Annals of Oncology 29, pages iv111-iv125.
Crossref
Crossref
Bart J. Morlion, Stefan A. Mueller-Lissner, Renato Vellucci, Wojciech Leppert, Benoît C. Coffin, Sara L. Dickerson & Tony O'Brien. (2018) Oral Prolonged-Release Oxycodone/Naloxone for Managing Pain and Opioid-Induced Constipation: A Review of the Evidence. Pain Practice 18:5, pages 647-665.
Crossref
Crossref
Satoshi Inoue, Yoji Saito, Satoru Tsuneto, Etsuko Aruga, Hiroshi Takahashi & Mitsutoshi Uemori. (2018) A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology 48:6, pages 542-547.
Crossref
Crossref
Nobuyuki KatakamiToshiyuki HaradaToru MurataKatsunori ShinozakiMasakazu TsutsumiTakaaki YokotaMasatsugu AraiYukio TadaMasaru NarabayashiNarikazu Boku. (2017) Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer. Journal of Clinical Oncology 35:34, pages 3859-3866.
Crossref
Crossref
David J. Copenhaver, Nicolas B. Karvelas & Scott M. Fishman. (2017) Risk Management for Opioid Prescribing in the Treatment of Patients With Pain From Cancer or Terminal Illness: Inadvertent Oversight or Taboo?. Anesthesia & Analgesia 125:5, pages 1610-1615.
Crossref
Crossref
Francesco Amato, Silvia Ceniti, Sergio Mameli, Giovanni M. Pisanu, Renato Vellucci, Vincenzo Palmieri, Leonardo Consoletti, Dorotea Magaldi, Paolo Notaro & Claudio Marcassa. (2017) High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain. Supportive Care in Cancer 25:10, pages 3051-3058.
Crossref
Crossref
Kaoru Toyama, Hidetoshi Furuie, Kana Kuroda & Hitoshi Ishizuka. (2017) Pharmacokinetic Bioequivalence Studies of an Extended-Release Oxycodone Hydrochloride Tablet in Healthy Japanese Subjects Under Fasting and Fed Conditions Without an Opioid Antagonist. Drugs in R&D 17:3, pages 363-370.
Crossref
Crossref
Martin Hale, James Wild, Jyotsna Reddy, Tadaaki Yamada & Juan Camilo Arjona Ferreira. (2017) Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials. The Lancet Gastroenterology & Hepatology 2:8, pages 555-564.
Crossref
Crossref
Nobuyuki KatakamiKoji OdaKatsunori TauchiKen NakataKatsunori ShinozakiTakaaki YokotaYura SuzukiMasaru NarabayashiNarikazu Boku. (2017) Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer. Journal of Clinical Oncology 35:17, pages 1921-1928.
Crossref
Crossref
Richard J. Bodnar. (2017) Endogenous Opiates and Behavior: 2015. Peptides 88, pages 126-188.
Crossref
Crossref
Oscar Corli & Anna Roberto. (2016) Good and Bad Responses to a Pain Therapy: How to Discriminate Between Them?. Journal of Clinical Oncology 34:29, pages 3579-3579.
Crossref
Crossref
Feifang He, Yilei Jiang & Li Li. (2016) The effect of naloxone treatment on opioid-induced side effects. Medicine 95:37, pages e4729.
Crossref
Crossref
Gareth P. Jones & Shiva S. Tripathi. (2016) Oxycodone and Naloxone Combination: A 12-Week Follow-up in 20 Patients Shows Effective Analgesia Without Opioid-Induced Bowel Dysfunction. Pain and Therapy 5:1, pages 107-113.
Crossref
Crossref